Expand NUVB Menu
NUVB MENU

NUVB Latest Press Releases

-- March 2, 2026 --

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PRNewswire 4:05 PM

-- February 25, 2026 --

Nuvation Bio to Participate in Upcoming Investor Conferences PRNewswire 4:05 PM

-- February 17, 2026 --

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 PRNewswire 4:05 PM

-- February 9, 2026 --

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma Business Wire 8:00 AM

-- January 12, 2026 --

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference Business Wire 8:00 AM
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan Business Wire 7:30 AM

-- January 6, 2026 --

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:05 PM

-- December 6, 2025 --

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List PRNewswire 10:40 PM

-- December 3, 2025 --

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology Business Wire 8:00 AM

-- November 26, 2025 --

Nuvation Bio to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- November 3, 2025 --

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update Business Wire 4:05 PM

-- October 30, 2025 --

Nuvation Bio to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- October 23, 2025 --

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma Business Wire 7:30 AM

-- October 20, 2025 --

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 Business Wire 4:05 PM

-- October 8, 2025 --

NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street PRNewswire 8:55 AM
Market Data Delayed 15 Minutes